MedTrace Logo

Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

NCT07268586 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2026-03-10

No results posted yet for this study

Summary

People with acute inferior wall myocardial infarction will be given an intravenous drug called atropine that increases the heart rate to check if it prevents heart rhythm disturbances during performing coronary intervention

Conditions

Interventions

DRUG

Intravenous atropine immediately before wire crossing during primary percutaneous coronary intervention

Intravenous atropine 1 mg immediately before wire crossing during primary percutaneous coronary intervention

DRUG

Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention

Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-02-28
Completion
2026-02-28
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07268586 on ClinicalTrials.gov